MLV & Co. Initiates SciClone Pharmaceuticals At Buy

Analysts at MLV & Co. initiated coverage on

with a Buy rating. The target price for SciClone Pharmaceuticals is set to $15. SciClone Pharmaceuticals shares have gained 78.29 percent over the past 52 weeks, while the S&P 500 index has surged 7.17 percent in the same period. SciClone Pharmaceuticals' shares fell 0.21 percent to close at $9.36 on Friday.